Form 4: Cidara Therapeutics Director Granted Stock Options Valued at $21.31 Per Share

Cidara Therapeutics, Inc. Director Bonnie L. Bassler was granted 11,100 stock options with an exercise price of $21.31 per share, vesting on the earlier of June 18, 2026, or the day prior to the company's 2026 annual meeting.

Summary

• Bonnie L. Bassler, a Director of Cidara Therapeutics, Inc. (CDTX), was granted 11,100 stock options.
• The stock options have an exercise price of $21.31 per share.
• The transaction date for this grant was June 18, 2025.
• The shares subject to the option will vest on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 annual meeting of stockholders.
• The options have an expiration date of June 17, 2035.
• Following this transaction, Bonnie L. Bassler beneficially owns 11,100 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The document reports a routine insider transaction (stock option grant) which is a standard part of director compensation and does not inherently convey positive or negative sentiment regarding the company's performance or outlook.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard form of compensation for directors, indicating ongoing commitment and engagement from the board.

Future Outlook

The document does not contain any forward-looking statements or guidance beyond the vesting schedule and expiration date of the granted options.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including for companies like Cidara Therapeutics, as a form of equity compensation to attract and retain talent and align leadership incentives with shareholder value creation.

Related Party Transactions

• The stock option grant to Director Bonnie L. Bassler constitutes a transaction with a related party, as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options gain value if the stock price increases.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The granted stock options will vest on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 annual meeting of stockholders.
• The options can be exercised by the director at the specified exercise price until their expiration date of June 17, 2035.

Key Dates

Keywords

Cidara Therapeutics, CDTX, Stock Option Grant, Insider Transaction, Form 4, Director Compensation, Equity Compensation